Surge in geriatric population, rise in the numberof hemophilic patients worldwide along with increase in prevalence of chronic diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia would drive the growth of the global intravenous immunoglobulin (IVIG) market.
Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/325
The global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Among applications, the myasthenia gravis segment is projected to grow at the fastest CAGR of 10.1% from 2018 to 2022, owing to significant rise in the incidence of this disease. At present, there are nearly 60,000 cases of this disease in the U.S. The prevalence of the disease is expected to grow in future, which needs treatment using IVIG. The hypogammaglobulinemia segment occupied more than one-fifth share of the global market in 2017 and is expected to continue its dominance throughout the forecast period of 2018-2022. The report also analyses segments such as chronic inflammatory demyelinating polyneuropathy, immunodeficiency disease, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others.
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/325
North America to continue its dominance throughout 2022
North America occupied nearly half of the global market revenue in 2017 and is expected to retain its dominance from 2018 to 2022, owing to the high adoption rate of IVIG treatments across countries in the region supplemented with the presence of high-profile plasma production facilities. Meanwhile, LAMEA is expected to grow at the highest CAGR of 10% during the forecast period, as the region has witnessed a significant increase in the incidence of immunological & neurological diseases. The other regions analyzed in the report include Europe and Asia-Pacific.
Key market players
The key players analyzed in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Shire (Baxalta), and Bayer AG. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.